TNM cancer staging: can it help develop a novel staging system for type 2 diabetes?

References

• Dall TM Yang W Halder P The economic burden of elevated blood glucose levels in 2012: diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes Diabetes Care 2014 37 12 3172 3179 25414388
   PubMed Web of Science ®Google Scholar
• Boyle JP Thompson TJ Gregg EW Barker LE Williamson DF Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence Popul Health Metr 2010 8 29 20969750
   PubMed Web of Science ®Google Scholar
• Odicino F Pecorelli S Zigliani L Creasman WT History of the FIGO cancer staging system Int J Gynaecol Obstet 2008 101 2 205 210 18199437
   PubMed Web of Science ®Google Scholar
• Chen G McQuade JL Panka DJ Clinical, molecular, and immune analysis of dabrafenib-trametinib combination treatment for braf inhibitor-refractory metastatic melanoma: a phase 2 clinical trial JAMA Oncol 2016 2 8 1056 1064 27124486
   PubMed Web of Science ®Google Scholar
• Gibson OR Segal L McDermott RA A simple diabetes vascular severity staging instrument and its application to a Torres Strai Islander and aboriginal adult cohort in North Australia BM Health Services Research 2012 12 185
   PubMed Web of Science ®Google Scholar
• García de Alba JE Salcedo Rocha AL Colunga Rodríguez C González Barrera JA Herrera Solís E Milke Najar ME UISESS scale for staging and classifying clinical-epidemiological risk in type 2 diabetes mellitus and for establishing multidisciplinary preventive actions Prev Med 2005 41 1 211 218 15917013
   PubMed Web of Science ®Google Scholar
• Wu SL Staging of type 2 diabetes mellitus Genet Mol Res 2015 14 1 2118 2121 25867358
   PubMed Web of Science ®Google Scholar
• White P Classification of obstetric diabetes Am J Obstet Gynecol 1978 130 2 228 230 619663
   PubMed Web of Science ®Google Scholar
• Levey AS Coresh J Balk E National Kidney Foundation National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification Ann Intern Med 2003 139 2 137 147 12859163
   PubMed Web of Science ®Google Scholar
• Rao Kondapally Seshasai S Kaptoge S Thompson A Emerging Risk Factors Collaboration Diabetes mellitus, fasting glucose, and risk of cause-specific death N Engl J Med 2011 364 9 829 841 21366474
   PubMed Web of Science ®Google Scholar
• Alegre-Díaz J Herrington W López-Cervantes M Diabetes and Cause-Specific Mortality in Mexico City N Engl J Med 2016 375 20 1961 1971 27959614
   PubMed Web of Science ®Google Scholar
• Tancredi M Rosengren A Svensson AM Excess mortality among persons with type 2 diabetes N Engl J Med 2015 373 18 1720 1732 26510021
   PubMed Web of Science ®Google Scholar
• Baena-Díez JM Peñafiel J Subirana I FRESCO Investigators Risk of cause-specific death in individuals with diabetes: a competing risks analysis Diabetes Care 2016 39 11 1987 1995 27493134
   PubMed Web of Science ®Google Scholar
• Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37) U.K. Prospective Diabetes Study Group Diabetes Care 1999 22 7 1125 1136 10388978
   PubMed Web of Science ®Google Scholar
• Coffey JT Brandle M Zhou H Valuing health-related quality of life in diabetes Diabetes Care 2002 25 12 2238 2243 12453967
   PubMed Web of Science ®Google Scholar
• Redekop WK Koopmanschap MA Stolk RP Rutten GE Wolffenbuttel BH Niessen LW Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes Diabetes Care 2002 25 3 458 463 11874930
   PubMed Web of Science ®Google Scholar
• Glasgow RE Ruggiero L Eakin EG Dryfoos J Chobanian L Quality of life and associated characteristics in a large national sample of adults with diabetes Diabetes Care 1997 20 4 562 567 9096981
   PubMed Web of Science ®Google Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) UK Prospective Diabetes Study (UKPDS) Group Lancet 1998 352 9131 854 865 9742977
   PubMed Web of Science ®Google Scholar
• Zinman B Wanner C Lachin JM EMPA-REG OUTCOME Investigators Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 2015 373 22 2117 2128 26378978
   PubMed Web of Science ®Google Scholar
• Marso SP Daniels GH Brown-Frandsen K LEADER Steering Committee; LEADER Trial Investigators Liraglutide and cardiovascular outcomes in type 2 diabetes N Engl J Med 2016 375 4 311 322 27295427
   PubMed Web of Science ®Google Scholar
• Ridker PM Revkin J Amarenco P SPIRE Cardiovascular Outcome Investigators Cardiovascular efficacy and safety of bococizumab in high-risk patients N Engl J Med 2017 376 16 1527 1539 28304242
   PubMed Web of Science ®Google Scholar
• Sabatine MS Giugliano RP Keech AC FOURIER Steering Committee and Investigators Evolocumab and clinical outcomes in patients with cardiovascular disease N Engl J Med 2017 376 18 1713 1722 28304224
   PubMed Web of Science ®Google Scholar
• Patz A Fire S Finkelstein D Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings Ophthalmology 1978 85 1 82 106 345173
   PubMed Web of Science ®Google Scholar
• Nguyen QD Shah SM Khwaja AA READ-2 Study Group Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study Ophthalmology 2010 117 11 2146 2151 20855114
   PubMed Web of Science ®Google Scholar
• Keech AC Mitchell P Summanen PA FIELD study investigators Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial Lancet 2007 370 9600 1687 1697 17988728
   PubMed Web of Science ®Google Scholar
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy Heart Outcomes Prevention Evaluation Study Investigators Lancet 2000 355 9200 253 259 10675071
   PubMed Web of Science ®Google Scholar
• Parving HH Lehnert H Bröchner-Mortensen J Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 2001 345 12 870 878 11565519
   PubMed Web of Science ®Google Scholar
• Vinik A Emir B Parsons B Cheung R Prediction of pregabalin-mediated pain response by severity of sleep disturbance in patients with painful diabetic neuropathy and post-herpetic neuralgia Pain Med 2014 15 4 661 670 24330406
   PubMed Web of Science ®Google Scholar
• Vinik A Emir B Cheung R Whalen E Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin Clin Ther 2013 35 5 612 623 23541708
   PubMed Web of Science ®Google Scholar
• Max MB Culnane M Schafer SC Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood Neurology 1987 37 4 589 596 2436092
   PubMed Web of Science ®Google Scholar
• Goldstein DJ Lu Y Detke MJ Lee TC Iyengar S Duloxetine vs. placebo in patients with painful diabetic neuropathy Pain 2005 116 1–2 109 118 15927394
   PubMed Web of Science ®Google Scholar
• Garber AJ Abrahamson MJ Barzilay JI Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2017 executive summary Endocr Pract 2017 23 2 207 238 28095040
   PubMed Web of Science ®Google Scholar
• Pantalone KM Misra-Hebert AD Hobbs TM Clinical inertia in type 2 diabetes management: evidence from a large, real-world data set Diabetes Care 2018 41 7 e113 e114 29678811
   PubMed Web of Science ®Google Scholar
• American Diabetes Association standards of medical care in diabetes–2018 Diabetes Care 2018 41 Suppl 1 S1 S153 29222369
   PubMed Web of Science ®Google Scholar